DPC-168

DPC-168 is an orally effective CCR3 antagonist (IC50 = 41 nM) . DPC-168 exhibits a significant ability to inhibit eosinophil chemotaxis and pulmonary inflammation. DPC-168 can be used for research on airway inflammation[1].

Product Specifications

CAS Number

[275810-55-4]

UNSPSC

12352005

Target

CCR

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Field of Research

Inflammation/Immunology

Smiles

O=C(N[C@H]1[C@H](CN2C[C@H](CC3=CC=C(F)C=C3)CCC2)CCCC1)NC4=CC=CC(C(C)=O)=C4

Molecular Formula

C28H36FN3O2

Molecular Weight

465.60

References & Citations

[1]D'Elios M M, et al. Interfering with chemokines and chemokine receptors as potential new therapeutic strategies[J]. Expert Opinion on Therapeutic Patents, 2008, 18 (3) : 309-325.